4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ABIONYX Pharma SA (ABNX) operates in the Biotechnology industry and is headquartered in Balma, France with about 49 employees. Its market capitalization is roughly €85 million. In the fiscal year ended 2025-12-31, ABNX reported €4M in revenue and (€6M) in net income.
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | €4M | €5M | €5M | €5M |
| Gross Profit | €0M | €1M | €1M | €1M |
| Operating Income (EBIT) | (€5M) | (€4M) | (€3M) | (€4M) |
| Net Income | (€6M) | (€4M) | (€4M) | (€4M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €13M | €14M | €15M | €16M | — |
| Total Liabilities | €9M | €6M | €7M | €9M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABNX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms